Prospective multicenter observational study demonstrates clinical remission with risankizumab in refractory Crohn's disease of the pouch, highlighting its therapeutic potential.
Lay Summary In this prospective, multicenter observational study of highly refractory patients with Crohn’s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8% at 12 weeks.
No takes yet. Share an insight, caveat, or question.
Kayal et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: